New hope for Tough-to-Treat lymphoma: testing a powerful drug duo
NCT ID NCT07197307
Summary
This study is testing whether combining two newer lymphoma drugs, loncastuximab tesirine and epcoritamab, is safe and effective for patients whose aggressive B-cell lymphoma has returned or not responded to prior therapy. It will include 120 adults whose disease progressed after first-line treatment or after a specialized cell therapy (CAR-T). The main goal is to see how many patients achieve significant tumor shrinkage or remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGGRESSIVE DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Universitätsklinikum Münster, Medizinische Klinik A
Münster, 48149, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.